The Longest Round: NovImmune’s Eight-Year Series B
This article was originally published in Start Up
Several biotechs have kept a private financing round open for several years and extended beyond $100 million, but Swiss antibody firm NovImmune is taking the concept farther than anyone.
You may also be interested in...
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
The year's biggest M&A deal, along with billion dollar alliances marked out December's dealmaking credentials.
Five $1bn+ alliances were penned in November. Topping the list was a potential $4.5bn deal between Arcturus Therapeutics and CSL Seqirus.